Innovations (Europe)

 

Fantom Bioresorbable Scaffold

REVA Medical, Inc.
+1 (858) 966-3000
www.revamedical.com

KEY FEATURES

  • Radiopaque (visible under x-ray)
  • Thin struts: 125 μm
  • Deliverable with single-step inflation
  • Biocompatible, strong Tyrocore polymer
  • Complete resorption in approximately 4 years

REVA Medical, Inc. secured CE Mark for the Fantom Sirolimus-Eluting Bioresorbable Scaffold.

Fantom is the only bioresorbable scaffold (BRS) made from Tyrocore, REVA’s proprietary tyrosine-derived polymer. Tyrocore is inherently radiopaque, making Fantom the first and only BRS that is visible under x-ray. Fantom is designed with a thin strut profile while maintaining strength. Thinner profiles have been shown to improve deliverability and vessel healing.

“Fantom is new-generation BRS technology offering the novel Tyrocore polymer, thin struts, and visibility under x-ray angiography. This is an important advance for BRS, which have the potential to offer patients the benefits of a metallic stent without the complications of a life-long implant,” said Bernardo Cortese, MD, at the Fatebenefratelli Hospital in Milan, Italy, in a company press release.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.